Centre for Trials Research, Cardiff University, Cardiff, UK.
Centre for Educational Development, Appraisal, and Research (CEDAR) University of Warwick, Coventry, UK.
Health Technol Assess. 2022 Jun;26(29):1-140. doi: 10.3310/TQGE0020.
Carers report unmet need for occupational therapy services addressing sensory difficulties in autism, yet insufficient evidence exists to recommend a therapeutic approach.
Our aim was to determine the clinical effectiveness and cost-effectiveness of sensory integration therapy for children with autism and sensory difficulties across behavioural, functional and quality-of-life outcomes.
We carried out a parallel-group randomised controlled trial, incorporating an internal pilot and a process evaluation. Randomisation utilised random permuted blocks.
Children were recruited via services and self-referral in Wales and England. Inclusion criteria were having an autism diagnosis, being in mainstream primary education and having definite/probable sensory processing difficulties. Exclusion criteria were having current/previous sensory integration therapy and current applied behaviour analysis therapy.
The intervention was manualised sensory integration therapy delivered over 26 weeks and the comparator was usual care.
The primary outcome was problem behaviours (determined using the Aberrant Behavior Checklist), including irritability/agitation, at 6 months. Secondary outcomes were adaptive behaviour, functioning and socialisation (using the Vineland Adaptive Behavior Scales); carer stress (measured using the Autism Parenting Stress Index); quality of life (measured using the EuroQol-5 Dimensions and Carer Quality of Life); functional change (according to the Canadian Occupational Performance Measure); sensory processing (determined using the Sensory Processing Measure™ at screening and at 6 months to examine mediation effects); and cost-effectiveness (assessed using the Client Service Receipt Inventory). Every effort was made to ensure that outcome assessors were blind to allocation.
A total of 138 participants were randomised ( = 69 per group). Usual care was significantly different from the intervention, which was delivered with good fidelity and adherence and minimal contamination, and was associated with no adverse effects. Trial procedures and outcome measures were acceptable. Carers and therapists reported improvement in daily functioning. The primary analysis included 106 participants. There were no significant main effects of the intervention at 6 or 12 months. The adjusted mean difference between groups on the Aberrant Behavior Checklist - irritability at 6 months post randomisation was 0.40 (95% confidence interval -2.33 to 3.14; = 0.77). Subgroup differences in irritability/agitation at 6 months were observed for sex of child (intervention × female = 6.42, 95% confidence interval 0.00 to 12.85; = 0.050) and attention deficit hyperactivity disorder (intervention × attention deficit hyperactivity disorder = -6.77, 95% confidence interval -13.55 to -0.01; = 0.050). There was an effect on carer stress at 6 months by region (intervention × South England = 7.01, 95% confidence interval 0.45 to 13.56; = 0.04) and other neurodevelopmental/genetic conditions (intervention × neurodevelopmental/genetic condition = -9.53, 95% confidence interval -18.08 to -0.98; = 0.030). Carer-rated goal performance and satisfaction increased across sessions ( < 0.001), with a mean change of 2.75 (95% confidence interval 2.14 to 3.37) for performance and a mean change of 3.34 (95% confidence interval 2.63 to 4.40) for satisfaction. Health economic evaluation suggests that sensory integration therapy is not cost-effective compared with usual care alone.
Limitations included variability of the intervention setting (i.e. NHS vs. private), delay for some receiving therapy, an error in administration of Vineland Adaptive Behavior Scales and no measurement of comparator arm goal performance.
The intervention did not demonstrate clinical benefit above standard care. Subgroup effects are hypothesis-generating only. The intervention is likely to be effective for individualised performance goals, although it is unclear whether effects were in addition to standard care or were maintained.
Further investigation of subgroup effects is needed.
This trial is registered as ISRCTN14716440.
This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and will be published in full in ; Vol. 26, No. 29. See the NIHR Journals Library website for further project information.
照顾者报告称,自闭症患者的感官困难需要职业治疗服务,但目前证据不足,无法推荐治疗方法。
我们旨在确定感觉统合疗法对自闭症和感官困难儿童的临床效果和成本效益,以行为、功能和生活质量结果为指标。
我们进行了一项平行组随机对照试验,纳入了内部试点和过程评估。随机化使用随机排列的块。
参与者通过威尔士和英格兰的服务和自我推荐招募。纳入标准为自闭症诊断、在主流小学教育中、明确/可能的感觉处理困难。排除标准为当前/以前的感觉统合治疗和当前的应用行为分析治疗。
干预措施是经过规范的感觉统合治疗,共 26 周,对照组为常规护理。
共有 138 名参与者被随机分组( = 69 人/组)。常规护理与干预组有显著差异,干预组治疗效果良好,具有较高的可信度和可接受性,并且没有出现不良影响。试验程序和结果测量方法是可以接受的。照顾者和治疗师报告说日常功能有所改善。主要分析包括 106 名参与者。干预组在 6 个月和 12 个月时的主要效果均无显著差异。随机分组后 6 个月时,异常行为检查表上的烦躁/激动的组间调整平均差异为 0.40(95%置信区间 -2.33 至 3.14; = 0.77)。在 6 个月时,儿童的性别(干预 × 女性 = 6.42,95%置信区间 0.00 至 12.85; = 0.050)和注意力缺陷多动障碍(干预 × 注意力缺陷多动障碍 = -6.77,95%置信区间 -13.55 至 -0.01; = 0.050)的亚组差异在烦躁/激动方面有统计学意义。6 个月时,地区(干预 × 英格兰南部 = 7.01,95%置信区间 0.45 至 13.56; = 0.04)和其他神经发育/遗传条件(干预 × 神经发育/遗传条件 = -9.53,95%置信区间 -18.08 至 -0.98; = 0.030)对父母报告的目标表现和满意度有影响。照顾者评定的目标表现和满意度在治疗过程中均有所提高( < 0.001),表现的平均变化为 2.75(95%置信区间 2.14 至 3.37),满意度的平均变化为 3.34(95%置信区间 2.63 至 4.40)。健康经济学评价表明,与单独常规护理相比,感觉统合治疗并不具有成本效益。
局限性包括干预设置的可变性(即 NHS 与私人)、一些接受治疗的延迟、Vineland 适应行为量表的管理错误以及没有测量对照组的目标表现。
干预措施在常规护理基础上未显示出临床获益。亚组效应仅具有生成假设的作用。该干预措施可能对个性化表现目标有效,但尚不清楚其效果是否是在常规护理之外还是得到了维持。
需要进一步研究亚组效应。
本试验在英国国家卫生与保健优化研究所(NIHR)健康技术评估计划下注册,并将在 ; Vol. 26, No. 29 中全文发表。有关该项目的更多信息,请访问 NIHR 期刊库网站。